EUVIMEDEUVIMED entdecken
Crossref

Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance

Teresa Ramone, Arianna Ghirri, Alessandro Prete, Antonio Matrone iD, Raffaele Ciampi iD, Paolo Piaggi, Maria Scutari, Teresa Rago, Liborio Torregrossa, Cristina Romei iD, Rossella Elisei iD, Eleonora Molinaro

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Teresa Ramone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa 56124, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Cancer, Papillary, Watchful Waiting, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: European Union-NextGenerationEU, Italian Ministry of University and Research, European Union or the European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The active surveillance (AS) program for papillary thyroid carcinoma (≤1 cm) at low risk (mPTC) showed a low percentage of progression.

Objective

The aim of this study was to find a molecular signature of cases that showed disease progression during AS, which would allow their early identification.

Methods

We performed next-generation sequencing of 95 fine-needle aspiration cytology specimens from cases prospectively enrolled in the AS program to analyze key somatic driver alterations or gene fusions implicated in PTC tumorigenesis. TERT promoter analysis was performed using Sanger sequencing or droplet digital polymerase chain reaction.

Results

BRAF p.V600E was found in 66.3% (63/95) of mPTC and was the most common somatic alteration, followed by RAS oncogene mutations detected in 3.2% of mPTC (3/95: 2 NRAS and 1 KRAS) and gene fusions detected in 3.2% of mPTC (3/95: 1 RET-PTC1, 1 TFG-NTRK1, 1 ALK imbalance). No TERT promoter mutations (C228T and C250T) were found in the analyzed mPTC (84/95). The comparison between the molecular profile and the clinical outcome of the mPTC (stable vs progressive disease) showed no correlation (P = .6) and did not identify a molecular signature able to identify progressive mPTC.

Conclusion

The molecular profile of mPTC is like that of bigger PTC with the exception that none of them showed a TERT promoter mutation. The identification of the most common driver mutations, such as BRAF, RAS, or gene fusions, is not helpful for the early identification of mPTC that will show disease progression during follow-up in the AS program.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid Cancer, PapillaryWatchful WaitingBiomarkers, TumorHumansFemaleMaleMiddle AgedAdultProto-Oncogene Proteins B-rafTelomeraseDisease ProgressionAgedMutationHigh-Throughput Nucleotide SequencingBiopsy, Fine-NeedleYoung AdultProspective StudiesPromoter Regions, Genetic

Stichwörter der Autor:innen

NGSactive surveillancemPTCmolecular profileprogression

Substanzen

Proto-Oncogene Proteins B-rafTelomeraseTERT protein, humanBRAF protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa 56124, Italy.
  • Department of Information Engineering, University of Pisa, Pisa 56124, Italy.
  • Department of Surgical, Medical and Molecular Pathology, University of Pisa, Pisa 56124, Italy.

ORCID-Profile: Antonio Matrone, Raffaele Ciampi, Cristina Romei, Rossella Elisei

Förderung

  • European Union-NextGenerationEU
  • Italian Ministry of University and Research
  • European Union or the European Commission
  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • European Union—NextGenerationEU
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Zitieren

APA

Ramone, T., Ghirri, A., Prete, A., Matrone, A., Ciampi, R., Piaggi, P., Scutari, M., Rago, T., Torregrossa, L., Romei, C., Elisei, R., & Molinaro, E. (2025). Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae575

Vancouver

Ramone T, Ghirri A, Prete A, Matrone A, Ciampi R, Piaggi P, et al. Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae575

BibTeX
@article{Ramone2025,
  author = {Ramone, Teresa and Ghirri, Arianna and Prete, Alessandro and Matrone, Antonio and Ciampi, Raffaele and Piaggi, Paolo and Scutari, Maria and Rago, Teresa and Torregrossa, Liborio and Romei, Cristina and Elisei, Rossella and Molinaro, Eleonora},
  title = {Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae575}
}
Kostenlos starten →